DE60140461D1 - Muc1 extrazelluläre domäne und zusammensetzungen für krebsbehandlung, und davon abgeleitete verfahren - Google Patents
Muc1 extrazelluläre domäne und zusammensetzungen für krebsbehandlung, und davon abgeleitete verfahrenInfo
- Publication number
- DE60140461D1 DE60140461D1 DE60140461T DE60140461T DE60140461D1 DE 60140461 D1 DE60140461 D1 DE 60140461D1 DE 60140461 T DE60140461 T DE 60140461T DE 60140461 T DE60140461 T DE 60140461T DE 60140461 D1 DE60140461 D1 DE 60140461D1
- Authority
- DE
- Germany
- Prior art keywords
- extracellular domain
- compositions
- cancer treatment
- muc1
- muc1 extracellular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23184100P | 2000-09-11 | 2000-09-11 | |
PCT/US2001/028548 WO2002022685A2 (en) | 2000-09-11 | 2001-09-11 | Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60140461D1 true DE60140461D1 (de) | 2009-12-24 |
Family
ID=22870825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60140461T Expired - Lifetime DE60140461D1 (de) | 2000-09-11 | 2001-09-11 | Muc1 extrazelluläre domäne und zusammensetzungen für krebsbehandlung, und davon abgeleitete verfahren |
Country Status (10)
Country | Link |
---|---|
US (3) | US20050053606A1 (de) |
EP (1) | EP1317278B1 (de) |
JP (1) | JP5165175B2 (de) |
KR (1) | KR20030068536A (de) |
CN (1) | CN1455680A (de) |
AT (1) | ATE447965T1 (de) |
AU (1) | AU9263101A (de) |
CA (1) | CA2421751C (de) |
DE (1) | DE60140461D1 (de) |
WO (1) | WO2002022685A2 (de) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5324732B2 (ja) | 2000-05-23 | 2013-10-23 | スネス ファーマシューティカルズ インコーポレイテッド | Nrg−2核酸分子、ポリペプチド、ならびに診断および治療法 |
US20040018181A1 (en) * | 2000-09-11 | 2004-01-29 | KUFE Donald W. | MUC1 interference RNA compositions and methods derived therefrom |
WO2002022685A2 (en) * | 2000-09-11 | 2002-03-21 | Kufe Donald W | Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom |
JP4564714B2 (ja) | 2000-11-27 | 2010-10-20 | ミナーヴァ・バイオテクノロジーズ・コーポレーション | 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法 |
US20020110841A1 (en) * | 2000-12-22 | 2002-08-15 | KUFE Donald W. | Regulation of cell growth by MUC1 |
IL158126A0 (en) * | 2001-03-29 | 2004-03-28 | Univ Ramot | Peptides and antibodies to muc 1 proteins |
US8435529B2 (en) * | 2002-06-14 | 2013-05-07 | Immunomedics, Inc. | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
AU2003225009A1 (en) * | 2002-04-22 | 2003-11-03 | Dyax Corporation | Antibodies specific for mucin polypeptide |
US9599619B2 (en) * | 2002-06-14 | 2017-03-21 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
US8821868B2 (en) * | 2002-06-14 | 2014-09-02 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
EP1536814A4 (de) * | 2002-07-03 | 2006-02-15 | Immunogen Inc | Antik rper gegen non-shed-muc1 und muc16, und ihre verwendungen |
CA2537263C (en) * | 2002-11-27 | 2017-05-30 | Minerva Biotechnologies Corporation | Techniques and compositions for the diagnosis and treatment of cancer (muc1) |
US20080090770A1 (en) * | 2003-04-11 | 2008-04-17 | Belmares Michael P | Modulation of Muc1 Mediated Signal Transduction |
US9005613B2 (en) * | 2003-06-16 | 2015-04-14 | Immunomedics, Inc. | Anti-mucin antibodies for early detection and treatment of pancreatic cancer |
AU2003904201A0 (en) | 2003-08-11 | 2003-08-21 | Allen, Barry John Mr | Alpha-conjugate of C595 for therapy of pancreatic, prostate and other cancers |
DK2363410T3 (en) * | 2003-08-26 | 2018-01-15 | Minerva Biotechnologies Corp | ISOFORMER OF MUC1 |
US8129506B2 (en) | 2003-10-24 | 2012-03-06 | Genzyme Corporation | Modulation of the interaction of MUC1 with MUC1 ligands |
EP1697399B1 (de) * | 2003-12-12 | 2016-11-23 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS | Epitop humaner zytotoxischer t-lymphozyten und dessen agonistenepitop aus der nichtvariablen zahl der tandem-wiederholungssequenz von muc-1 |
WO2005082458A1 (en) * | 2004-02-23 | 2005-09-09 | Genzyme Corporation | Muc1 antagonist enhancement of death receptor ligand-induced apoptosis |
CA2595778A1 (en) * | 2005-01-28 | 2006-08-03 | Ramot At Tel Aviv University, Ltd. | Anti-muc1 .alpha..beta. antibodies |
JP2008537095A (ja) * | 2005-02-15 | 2008-09-11 | ダナ−ファーバー キャンサー インスティテュート インク. | Muc1活性の調節 |
WO2006114115A1 (de) | 2005-04-26 | 2006-11-02 | Trion Pharma Gmbh | Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs |
WO2007024940A2 (en) * | 2005-08-22 | 2007-03-01 | Dana-Farber Cancer Institute, Inc. | Mitochondrial localization of muc1 |
JP2009511586A (ja) * | 2005-10-11 | 2009-03-19 | ワシントン・ユニバーシティ | 気道分泌過多を治療するための組成物および方法 |
US8129345B2 (en) * | 2006-07-20 | 2012-03-06 | Dana-Farber Cancer Institute, Inc. | MUC1-IκB kinase complexes and their activities |
US20080107661A1 (en) * | 2006-07-28 | 2008-05-08 | Dana-Farber Cancer Institute, Inc. | MUC1 and ABL |
CN101652469B (zh) * | 2006-12-06 | 2014-04-16 | 米纳瓦生物技术公司 | 用于鉴定和操作细胞的方法 |
US8420591B2 (en) * | 2006-12-08 | 2013-04-16 | Dana-Farber Cancer Institute, Inc. | MUC1 and galectin-3 |
US7972870B2 (en) | 2007-02-02 | 2011-07-05 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3 |
US7871784B2 (en) * | 2007-02-02 | 2011-01-18 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins |
US8012695B2 (en) | 2007-02-14 | 2011-09-06 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to promoter regulation by MUC1 and KLF proteins |
EP2337801A4 (de) | 2008-10-06 | 2012-07-25 | Minerva Biotechnologies Corp | Muc1*-antikörper |
MX2011004082A (es) | 2008-10-17 | 2011-10-14 | Dana Farber Cancer Inst Inc | Peptidos de dominio citoplasmico muc-1 como inhibidores del cancer. |
JP5702371B2 (ja) | 2009-05-27 | 2015-04-15 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Muc1のアンタゴニストを使用した、炎症の阻害 |
EA026732B1 (ru) * | 2009-06-11 | 2017-05-31 | Минерва Байотекнолоджиз Корпорейшн | Способы культивирования стволовых клеток и клеток-предшественников |
CN102713623A (zh) * | 2010-01-22 | 2012-10-03 | 免疫医疗公司 | 早期胰腺腺癌的检测 |
WO2011100688A1 (en) | 2010-02-12 | 2011-08-18 | Dana-Farber Cancer Institute, Inc. | Improved antagonists of muc1 |
US8993525B2 (en) * | 2010-10-14 | 2015-03-31 | Amicus Therapeutics, Inc. | Compounds and methods for treating or preventing disease conditions associated with α-1-antitrypsin |
CN103429263A (zh) * | 2011-02-15 | 2013-12-04 | 免疫医疗公司 | 用于胰腺癌早期检测和治疗的抗粘蛋白抗体 |
MX2013009742A (es) * | 2011-02-24 | 2014-01-31 | Oncothyreon Inc | Vacuna de glicolipopeptidos a base de muc1 con adyuvante. |
WO2013026015A1 (en) * | 2011-08-18 | 2013-02-21 | Dana-Farber Cancer Institute, Inc. | Muc1 ligand traps for use in treating cancers |
US9044421B2 (en) | 2012-03-28 | 2015-06-02 | Genus Oncology, Llc | Treating MUC1-expressing cancers with combination therapies |
WO2013161614A1 (ja) | 2012-04-27 | 2013-10-31 | コニカミノルタ株式会社 | 酵素処理工程を含むレクチンを用いた抗原検出方法 |
US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
US9452228B2 (en) | 2013-04-01 | 2016-09-27 | Immunomedics, Inc. | Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2) |
WO2014199780A1 (ja) * | 2013-06-12 | 2014-12-18 | マルハニチロ株式会社 | ジペプチジルペプチダーゼiv(dppiv)阻害ペプチド化合物、それを含有する組成物、及びその製造方法 |
JP6414078B2 (ja) | 2013-12-27 | 2018-10-31 | コニカミノルタ株式会社 | 診断用情報の分析方法およびそのためのキット |
JP6323463B2 (ja) * | 2013-12-27 | 2018-05-16 | コニカミノルタ株式会社 | 診断用情報の分析方法およびそのためのキット |
CN106132992B (zh) * | 2014-01-29 | 2020-08-07 | 达娜-法勃肿瘤研究所公司 | 针对muc1-c/胞外结构域(muc1-c/ecd)的抗体 |
CN103880956B (zh) * | 2014-03-10 | 2015-12-30 | 中国人民解放军第四军医大学 | 抗muc1单克隆抗体及其轻链和重链可变区 |
CA2976089A1 (en) | 2015-02-10 | 2016-08-18 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies |
WO2018174544A2 (ko) * | 2017-03-21 | 2018-09-27 | 주식회사 펩트론 | Muc1에 특이적으로 결합하는 항체 및 그의 용도 |
EP3604334A4 (de) | 2017-03-21 | 2021-03-31 | Peptron, Inc. | Spezifisch an muc1 bindende antikörper und verwendungen davon |
AU2018346955A1 (en) | 2017-10-13 | 2020-04-30 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
EP3759145A4 (de) * | 2018-02-26 | 2022-03-09 | Minerva Biotechnologies Corporation | Diagnoseverfahren unter verwendung von anti-muc1*-antikörpern |
CN116536270A (zh) * | 2023-01-31 | 2023-08-04 | 浙江中医药大学 | 人卵巢癌细胞系SKOV3-sh-MUC1及其构建方法和应用 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4497796A (en) * | 1980-03-26 | 1985-02-05 | The Regents Of The University Of California | Gene transfer in intact mammals |
DE3369466D1 (en) * | 1982-05-12 | 1987-03-05 | Harvard College | Fused genes encoding hybrid proteins, cloning vectors containing them and the use thereof |
US5080898A (en) * | 1982-05-12 | 1992-01-14 | The University Hospital | Enzymatically active toxin coupled to a cell-specific ligand |
US4740461A (en) * | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US4894227A (en) * | 1986-08-01 | 1990-01-16 | Cetus Corporation | Composition of immunotoxins with interleukin-2 |
US6054438A (en) * | 1987-01-07 | 2000-04-25 | Imperial Cancer Research Technology Limited | Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin |
GB8725529D0 (en) * | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
US4963484A (en) * | 1988-01-29 | 1990-10-16 | Dana-Farber Cancer Institute, Inc. | Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen |
US5053489A (en) * | 1988-01-29 | 1991-10-01 | Dana-Farber Cancer Institute, Inc. | Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
FR2668064B1 (fr) * | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
US5331573A (en) * | 1990-12-14 | 1994-07-19 | Balaji Vitukudi N | Method of design of compounds that mimic conformational features of selected peptides |
US5776427A (en) * | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
JP3698370B2 (ja) | 1992-04-13 | 2005-09-21 | ダナ−ファーバー キャンサー インスティチュート インク | 癌腫抗原用抗体 |
WO1994016057A1 (en) * | 1992-12-31 | 1994-07-21 | Dana-Farber Cancer Institute, Inc. | Enhancer sequence for modulating expression in epithelial cells |
US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
GB9404270D0 (en) * | 1994-03-05 | 1994-04-20 | Delta Biotechnology Ltd | Yeast strains and modified albumins |
DK0773952T3 (da) * | 1994-07-20 | 2004-03-22 | Inst Genetics Llc | Interaktionsfældesystemer til påvisning af proteininteraktioner |
EP0694808B1 (de) * | 1994-07-29 | 2001-12-05 | Dainippon Ink And Chemicals, Inc. | Verfahren zur Herstellung von Negativbildern mit ultrahohem Kontrast und photographisches Silberhalogenidmaterial und Entwickler dafür |
JPH08176138A (ja) * | 1994-12-19 | 1996-07-09 | Mercian Corp | イソクマリン誘導体 |
US6074841A (en) * | 1996-08-19 | 2000-06-13 | Millennium Biotherapeutics, Inc. | Don-1 gene and polypeptides and uses therefor |
JP2002519669A (ja) * | 1998-06-26 | 2002-07-02 | バイオミラ,インコーポレイテッド | T細胞の活性化を検出する方法 |
IT1303683B1 (it) * | 1998-10-30 | 2001-02-23 | Menarini Ricerche Spa | Composizione farmaceutiche ad azione antitumorale contenente dnacodificante per frammenti di una proteina antigenica. |
AU2354700A (en) * | 1998-12-11 | 2000-06-26 | Biomira Inc. | Muc-1 antagonists and methods of treating immune disorders |
IL144559A0 (en) * | 1999-03-01 | 2002-05-23 | Genentech Inc | Antibodies for cancer therapy and diagnosis |
DE60016189T2 (de) * | 1999-03-26 | 2005-12-22 | Firmenich S.A. | Cyklische verbindungen sowie deren verwendung als vorstufen von duftalkoholen |
US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
US6589981B2 (en) * | 2000-02-29 | 2003-07-08 | Ilex Oncology, Inc. | Tumor radiosensitization and/or chemopotentiation using isocoumarin derivatives |
US20040018181A1 (en) * | 2000-09-11 | 2004-01-29 | KUFE Donald W. | MUC1 interference RNA compositions and methods derived therefrom |
WO2002022685A2 (en) * | 2000-09-11 | 2002-03-21 | Kufe Donald W | Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom |
US20020110841A1 (en) * | 2000-12-22 | 2002-08-15 | KUFE Donald W. | Regulation of cell growth by MUC1 |
US20040209832A1 (en) * | 2001-11-30 | 2004-10-21 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US6716627B2 (en) * | 2001-12-20 | 2004-04-06 | Isis Pharmaceuticals, Inc. | Antisense modulation of mucin 1, transmembrane expression |
US20080090770A1 (en) * | 2003-04-11 | 2008-04-17 | Belmares Michael P | Modulation of Muc1 Mediated Signal Transduction |
-
2001
- 2001-09-11 WO PCT/US2001/028548 patent/WO2002022685A2/en active Application Filing
- 2001-09-11 KR KR20037003194A patent/KR20030068536A/ko not_active Application Discontinuation
- 2001-09-11 CN CN01815471A patent/CN1455680A/zh active Pending
- 2001-09-11 AT AT01973008T patent/ATE447965T1/de not_active IP Right Cessation
- 2001-09-11 DE DE60140461T patent/DE60140461D1/de not_active Expired - Lifetime
- 2001-09-11 US US09/951,938 patent/US20050053606A1/en not_active Abandoned
- 2001-09-11 EP EP01973008A patent/EP1317278B1/de not_active Expired - Lifetime
- 2001-09-11 AU AU9263101A patent/AU9263101A/xx not_active Withdrawn
- 2001-09-11 JP JP2002526935A patent/JP5165175B2/ja not_active Expired - Fee Related
- 2001-09-11 CA CA2421751A patent/CA2421751C/en not_active Expired - Fee Related
-
2004
- 2004-02-13 US US10/778,859 patent/US20050042209A1/en not_active Abandoned
-
2009
- 2009-02-26 US US12/393,637 patent/US20090232812A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20030068536A (ko) | 2003-08-21 |
WO2002022685A2 (en) | 2002-03-21 |
EP1317278A2 (de) | 2003-06-11 |
CA2421751C (en) | 2014-02-11 |
AU9263101A (en) | 2002-03-26 |
JP5165175B2 (ja) | 2013-03-21 |
JP2004515472A (ja) | 2004-05-27 |
ATE447965T1 (de) | 2009-11-15 |
US20050053606A1 (en) | 2005-03-10 |
EP1317278B1 (de) | 2009-11-11 |
WO2002022685A3 (en) | 2002-09-26 |
US20090232812A1 (en) | 2009-09-17 |
CA2421751A1 (en) | 2002-03-21 |
CN1455680A (zh) | 2003-11-12 |
US20050042209A1 (en) | 2005-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60140461D1 (de) | Muc1 extrazelluläre domäne und zusammensetzungen für krebsbehandlung, und davon abgeleitete verfahren | |
DE602004015811D1 (de) | Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden | |
ATE459653T1 (de) | Monoklonale anti-cd71-antikörper und deren verwendung zur behandlung maligner tumorzellen | |
MX2007003470A (es) | Compuestos de carbonilo los cuales pueden utilizarse como inhibidores del factor de coagulacion xa. | |
RS48804A (en) | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers | |
WO2007081740A3 (en) | Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers | |
DK1706428T3 (da) | Anti-cancer-antistoffer med reduceret komplementfiksering | |
BRPI0515616A (pt) | anticorpos isolados que se ligam a polipeptìdeo, anticorpos isolados, métodos de inibição do crescimento de célula, métodos de detecção do nìvel de polipeptìdeo tat188, rna de interferência, vetor de expressão, célula hospedeira, composição de matéria, artigo industrializado, método de inibição do crescimento de célula cancerosa e método de tratamento ou prevenção de disfunção proliferativa celular | |
TN2009000255A1 (en) | Quinazolines for pdk1 inhibition | |
PT1255537E (pt) | Inibidores da proteina farnesil transferase para tratar cancro da mama | |
MXPA06010904A (es) | Inhibidores de pirazol cinasa triciclicos. | |
BRPI0511070A (pt) | compostos e processos para inibição da interação de proteìnas bcl com parceiros de ligação | |
WO2004044160A3 (en) | Muc1 interference rna compositions and methods derived therefrom | |
MY153232A (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners | |
TW200700089A (en) | Recombinant protein comprising starch binding domain and use thereof | |
DE69940320D1 (de) | Betulinsäurederivate zur inhibierung des krebswach | |
MXPA05009151A (es) | Inhibidores de cinasa heterociclica. | |
MX2007000364A (es) | Metodos para tratar cancer usando agentes que inhiben la senalizacion de wnt16. | |
ATE435647T1 (de) | Rutheniumkomplexe zur krebsbehandlung | |
MXPA05006507A (es) | Inhibidores de ccxckr2 expresado en tumor humano. | |
ATE339208T1 (de) | Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs | |
ATE423129T1 (de) | Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs | |
NO20055650L (no) | Ruteinum (II)-komplekser for behandling av tumorer | |
ATE445408T1 (de) | Verwendung von prolactin in der prophylaktischen krebstherapie | |
ATE329597T1 (de) | Die verwendung von einer 4- pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |